Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Becton, Dickinson and Company (BD) has announced the closure of its manufacturing plant in Israel, resulting in the layoff of 200 employees. This decision is part of a broader restructuring effort aimed at optimizing operations and reducing costs. The layoffs are expected to impact the local workforce significantly, as BD consolidates its manufacturing capabilities. The company has not specified a timeline for the closure, but it marks a strategic shift in its operational focus. This move reflects ongoing challenges in the manufacturing sector and BD's commitment to enhancing efficiency.
Becton, Dickinson and Company (BD) has announced plans to close its infusion and syringe pumps facility located in Israel. This decision is part of a broader restructuring effort aimed at streamlining operations and improving efficiency. While specific details regarding the number of employees affected have not been disclosed, the closure indicates a significant shift in BD's operational strategy. The company is focusing on optimizing its resources and aligning its workforce with current market demands. Further information about the timeline for the closure and potential layoffs is expected to be released as the plan develops.
No one has shared a story from Becton, Dickinson and Company yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.